NASDAQ:ABEO - Abeona Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.25 +0.20 (+1.25 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$16.25
Today's Range$16.00 - $16.55
52-Week Range$4.55 - $22.75
Volume639,278 shs
Average Volume1.09 million shs
Market Capitalization$781.72 million
P/E Ratio-24.62
Dividend YieldN/A
Beta1.27

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics logoAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABEO
CUSIPN/A
Phone214-665-9495

Debt

Debt-to-Equity RatioN/A
Current Ratio20.80
Quick Ratio20.80

Price-To-Earnings

Trailing P/E Ratio-24.62
Forward P/E Ratio-22.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$840,000.00
Price / Sales915.22
Cash FlowN/A
Price / CashN/A
Book Value$3.58 per share
Price / Book4.54

Profitability

EPS (Most Recent Fiscal Year)($0.66)
Net Income$-27,310,000.00
Net Margins-939.83%
Return on Equity-23.57%
Return on Assets-22.34%

Miscellaneous

Employees42
Outstanding Shares47,310,000

Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) posted its quarterly earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The biopharmaceutical company earned $2.60 million during the quarter, compared to analyst estimates of $0.27 million. Abeona Therapeutics had a negative return on equity of 23.57% and a negative net margin of 939.83%. View Abeona Therapeutics' Earnings History.

When is Abeona Therapeutics' next earnings date?

Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Abeona Therapeutics.

What price target have analysts set for ABEO?

8 analysts have issued 12 month price objectives for Abeona Therapeutics' shares. Their forecasts range from $23.00 to $36.00. On average, they expect Abeona Therapeutics' share price to reach $30.00 in the next year. View Analyst Ratings for Abeona Therapeutics.

What are Wall Street analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:
  • 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (5/21/2018)
  • 2. HC Wainwright analysts commented, "for ABO-202 in Batten Disease; Reiterate Buy Stock Data 04/19/2018 Price $20.05 Exchange NASDAQ Price Target $30.00 52-Week High $22.75 52-Week Low $4.55 Enterprise Value (M) $809.2 Market Cap (M) $947 Public Market Float (M) 24.7 Shares Outstanding (M) 47.2 3 Month Avg Volume 1,230,320 Short Interest (M) 7.59 Balance Sheet Metrics Cash (M) $137.8 Total Debt (M) $0.0 Total Cash/Share $2.92 Book Value/Share $3.63 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.17) (0.13) (0.18) 2Q (0.20) (0.21) (0.19) 3Q (0.08) (0.13) (0.21) 4Q (0.18) (0.19) (0.22) FY (0.64) (0.66) (0.81) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.2 0.2 0.4 2Q 0.2 0.2 0.4 3Q 0.2 0.2 0.4 4Q 0.3 0.2 0.4 FY 0.9 0.8 1.4 25 20 15 10 5 0 APR-17 AUG-17 DEC-17 APR-18 5 4 3 2 1 0 Vol. (mil) Price Orphan Drug Designation obtained for ABO-202 in Europe." (4/20/2018)
  • 3. Maxim Group analysts commented, "Abeona announced positive early data for ABO-101 in the first patient treated in the P1/2 trial for Sanfilippo Syndrome Type IIIB. As a reminder, this is the second gene therapy candidate targeting Sanfilippo Syndrome behind ABO-102, which has demonstrated positive data in 8 patients so far with Type IIIA disease. The difference between ABO-101 and ABO-102 is the replaced gene, same targeted pathway." (2/7/2018)

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

Has Abeona Therapeutics been receiving favorable news coverage?

Media coverage about ABEO stock has trended positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abeona Therapeutics earned a news impact score of 0.29 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.04 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (10.22%), FMR LLC (10.22%), BlackRock Inc. (3.97%), Millennium Management LLC (1.94%), Nexthera Capital LP (0.78%) and Northern Trust Corp (0.64%). View Institutional Ownership Trends for Abeona Therapeutics.

Which major investors are selling Abeona Therapeutics stock?

ABEO stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Barclays PLC, California Public Employees Retirement System and Alkeon Capital Management LLC. View Insider Buying and Selling for Abeona Therapeutics.

Which major investors are buying Abeona Therapeutics stock?

ABEO stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Nexthera Capital LP, Sphera Funds Management LTD., UBS Group AG, Cim Investment Mangement Inc., Trexquant Investment LP, Sabby Management LLC and Virginia Retirement Systems ET AL. View Insider Buying and Selling for Abeona Therapeutics.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $16.25.

How big of a company is Abeona Therapeutics?

Abeona Therapeutics has a market capitalization of $781.72 million and generates $840,000.00 in revenue each year. The biopharmaceutical company earns $-27,310,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Abeona Therapeutics employs 42 workers across the globe.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected]


MarketBeat Community Rating for Abeona Therapeutics (ABEO)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe ABEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABEO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abeona Therapeutics (NASDAQ:ABEO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Abeona Therapeutics in the last 12 months. Their average twelve-month price target is $30.00, suggesting that the stock has a possible upside of 84.62%. The high price target for ABEO is $36.00 and the low price target for ABEO is $23.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.00$30.4286$28.25$27.00
Price Target Upside: 84.62% upside44.21% upside56.08% upside67.18% upside

Abeona Therapeutics (NASDAQ:ABEO) Consensus Price Target History

Price Target History for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018Cantor FitzgeraldSet Price TargetBuy$36.00MediumView Rating Details
5/16/2018SunTrust BanksLower Price TargetBuy ➝ Positive$23.00HighView Rating Details
5/14/2018Maxim GroupSet Price TargetBuy$35.00LowView Rating Details
5/14/2018HC WainwrightSet Price TargetBuy$30.00HighView Rating Details
1/24/2018Royal Bank of CanadaReiterated RatingBuy$26.00LowView Rating Details
11/22/2017Jefferies GroupReiterated RatingBuy$28.00N/AView Rating Details
10/10/2017CitigroupInitiated CoverageBuy$32.00N/AView Rating Details
5/26/2017FBR & CoReiterated RatingBuyN/AView Rating Details
2/7/2017Rodman & RenshawReiterated RatingBuy$17.00 ➝ $20.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Abeona Therapeutics (NASDAQ:ABEO) Earnings History and Estimates Chart

Earnings by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.21)($0.19)($0.20)
Q2 20182($0.20)($0.18)($0.19)
Q3 20182($0.23)($0.18)($0.21)
Q4 20182($0.19)($0.16)($0.18)

Abeona Therapeutics (NASDAQ ABEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/2018        
5/14/2018Q1 2018($0.1860)($0.18)$0.27 million$2.60 millionViewListenView Earnings Details
3/16/2018Q4 2017($0.1410)($0.19)$0.24 million$0.22 millionViewN/AView Earnings Details
11/15/2017Q3 2017($0.1850)($0.13)$0.22 million$0.22 millionViewN/AView Earnings Details
8/15/2017Q2 2017($0.1420)($0.21)$0.21 million$0.22 millionViewN/AView Earnings Details
5/18/2017Q1 2017($0.15)($0.13)$0.28 million$0.19 millionViewN/AView Earnings Details
3/31/201712/31/2016($0.14)($0.19)$0.19 million$0.26 millionViewN/AView Earnings Details
11/14/2016Q316($0.19)($0.08)$0.23 million$0.18 millionViewN/AView Earnings Details
8/16/2016Q2($0.14)($0.20)$0.27 million$0.21 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.11)($0.17)$0.30 million$0.24 millionViewN/AView Earnings Details
3/30/2016Q1($0.13)($0.17)$0.22 millionViewN/AView Earnings Details
11/17/2015Q3 2015($0.11)($0.19)$0.33 million$0.29 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.10)($0.16)$0.15 million$0.28 millionViewN/AView Earnings Details
5/14/2015Q1 2015($0.10)$0.26 millionViewN/AView Earnings Details
11/14/2014Q3 2014($4.15)$0.24 millionViewN/AView Earnings Details
8/14/2014Q2 2014($3.00)$0.25 millionViewN/AView Earnings Details
5/12/2014Q1 2014($4.00)$0.21 millionViewN/AView Earnings Details
3/26/2014Q4 2013($3.50)$0.16 millionViewN/AView Earnings Details
11/14/2013Q3 2013($2.00)$0.19 millionViewN/AView Earnings Details
8/14/2013Q2 2013($5.50)$0.47 millionViewN/AView Earnings Details
5/16/2013Q1 2013($2.50)$1.22 millionViewN/AView Earnings Details
3/19/2013Q4 2012($4.00)ViewN/AView Earnings Details
11/14/2012Q3 2012($3.05)ViewN/AView Earnings Details
8/14/2012Q2 2012($4.40)ViewN/AView Earnings Details
5/15/2012Q1 2012($4.00)($2.70)ViewN/AView Earnings Details
3/23/2012Q4 2011($2.80)ViewN/AView Earnings Details
11/14/2011Q3 2011($7.50)($3.00)ViewN/AView Earnings Details
8/15/2011Q2 2011($7.85)ViewN/AView Earnings Details
5/16/2011Q1 2011($7.50)($7.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Abeona Therapeutics (NASDAQ:ABEO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Abeona Therapeutics (NASDAQ ABEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 68.62%
Insider Trading History for Abeona Therapeutics (NASDAQ:ABEO)
Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ ABEO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2016Todd WiderDirectorBuy5,000$5.48$27,400.0075,000View SEC Filing  
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abeona Therapeutics (NASDAQ ABEO) News Headlines

Source:
DateHeadline
Abeona Therapeutics Inc (ABEO) to Post FY2018 Earnings of ($0.89) Per Share, Cantor Fitzgerald ForecastsAbeona Therapeutics Inc (ABEO) to Post FY2018 Earnings of ($0.89) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - May 24 at 9:19 AM
Abeona Therapeutics (ABEO) PT Set at $36.00 by Cantor FitzgeraldAbeona Therapeutics (ABEO) PT Set at $36.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 23 at 10:54 AM
-$0.19 Earnings Per Share Expected for Abeona Therapeutics Inc (ABEO) This Quarter-$0.19 Earnings Per Share Expected for Abeona Therapeutics Inc (ABEO) This Quarter
www.americanbankingnews.com - May 23 at 3:18 AM
Abeona Therapeutics (ABEO) Announces Clinical Update on MPS IIIA Gene Therapy TrialAbeona Therapeutics (ABEO) Announces Clinical Update on MPS IIIA Gene Therapy Trial
www.streetinsider.com - May 22 at 9:45 AM
Abeona Therapeutics Inc (ABEO) Receives Consensus Rating of "Buy" from BrokeragesAbeona Therapeutics Inc (ABEO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 21 at 1:46 PM
Heres Why Abeona Therapeutics Stock Dropped 12% TodayHere's Why Abeona Therapeutics Stock Dropped 12% Today
www.msn.com - May 19 at 9:50 AM
Here's Why Abeona Therapeutics Stock Dropped 12% TodayHere's Why Abeona Therapeutics Stock Dropped 12% Today
finance.yahoo.com - May 19 at 9:50 AM
Abeo down 12% on gene therapy data in SanfilippoAbeo down 12% on gene therapy data in Sanfilippo
seekingalpha.com - May 18 at 11:13 AM
BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy TrialBRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial
www.reuters.com - May 18 at 11:13 AM
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT MeetingAbeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
finance.yahoo.com - May 18 at 11:13 AM
Abeona Therapeutics Inc Expected to Post Q2 2018 Earnings of ($0.18) Per Share (ABEO)Abeona Therapeutics Inc Expected to Post Q2 2018 Earnings of ($0.18) Per Share (ABEO)
www.americanbankingnews.com - May 18 at 8:00 AM
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT MeetingAbeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
finance.yahoo.com - May 17 at 10:03 AM
Q2 2018 EPS Estimates for Abeona Therapeutics Inc (ABEO) Lifted by AnalystQ2 2018 EPS Estimates for Abeona Therapeutics Inc (ABEO) Lifted by Analyst
www.americanbankingnews.com - May 17 at 7:00 AM
Abeona Therapeutics (ABEO) Buy Rating Reiterated at Cantor FitzgeraldAbeona Therapeutics' (ABEO) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - May 16 at 3:41 PM
Abeona Therapeutics (ABEO) PT Lowered to $23.00 at SunTrust BanksAbeona Therapeutics (ABEO) PT Lowered to $23.00 at SunTrust Banks
www.americanbankingnews.com - May 16 at 3:21 PM
Brokers Set Expectations for Abeona Therapeutics Incs FY2022 Earnings (ABEO)Brokers Set Expectations for Abeona Therapeutics Inc's FY2022 Earnings (ABEO)
www.americanbankingnews.com - May 16 at 8:20 AM
Edited Transcript of ABEO earnings conference call or presentation 14-May-18 2:00pm GMTEdited Transcript of ABEO earnings conference call or presentation 14-May-18 2:00pm GMT
finance.yahoo.com - May 15 at 10:34 AM
JFs Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 PositionsJF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
www.msn.com - May 14 at 4:06 PM
Abeona Therapeutics (ABEO) CEO Carsten Thiel on Q1 2018 Results - Earnings Call TranscriptAbeona Therapeutics' (ABEO) CEO Carsten Thiel on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 4:06 PM
Abeona Therapeutics Inc (NASDAQ:ABEO): Does The -41.52% Earnings Drop Reflect A Longer Term Trend?Abeona Therapeutics Inc (NASDAQ:ABEO): Does The -41.52% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - May 14 at 4:06 PM
Maxim Group Analysts Give Abeona Therapeutics (ABEO) a $35.00 Price TargetMaxim Group Analysts Give Abeona Therapeutics (ABEO) a $35.00 Price Target
www.americanbankingnews.com - May 14 at 3:36 PM
Abeona Therapeutics (ABEO) Given a $30.00 Price Target at HC WainwrightAbeona Therapeutics (ABEO) Given a $30.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 14 at 12:43 PM
Eiger: A Hidden Gem Creates A Lot Of Upside PotentialEiger: A Hidden Gem Creates A Lot Of Upside Potential
seekingalpha.com - May 14 at 11:14 AM
Abeona Therapeutics (ABEO) Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of DirectorsAbeona Therapeutics (ABEO) Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
www.streetinsider.com - May 14 at 11:14 AM
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of DirectorsAbeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
finance.yahoo.com - May 14 at 11:14 AM
Abeona Therapeutics (ABEO) Posts  Earnings Results, Beats Expectations By $0.01 EPSAbeona Therapeutics (ABEO) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 12 at 11:15 AM
Abeona Therapeutics (ABEO) Tops Q1 EPS by 1cAbeona Therapeutics (ABEO) Tops Q1 EPS by 1c
www.streetinsider.com - May 11 at 11:08 AM
BRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per ShareBRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share
www.reuters.com - May 11 at 11:08 AM
Abeona Therapeutics beats by $0.01, beats on revenueAbeona Therapeutics beats by $0.01, beats on revenue
seekingalpha.com - May 11 at 11:08 AM
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business HighlightsAbeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
finance.yahoo.com - May 11 at 11:08 AM
Abeona Therapeutics: 1Q Earnings SnapshotAbeona Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 11:08 AM
Access Pharmaceuticals (ABEO) Stock Rating Upgraded by BidaskClubAccess Pharmaceuticals (ABEO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 9 at 6:47 PM
Access Pharmaceuticals (ABEO) Given a $35.00 Price Target by Maxim Group AnalystsAccess Pharmaceuticals (ABEO) Given a $35.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - May 8 at 3:28 PM
Abeona Therapeutics Announces Upcoming PresentationsAbeona Therapeutics Announces Upcoming Presentations
finance.yahoo.com - May 8 at 9:50 AM
 Analysts Anticipate Access Pharmaceuticals Inc. (ABEO) Will Announce Quarterly Sales of $270,000.00 Analysts Anticipate Access Pharmaceuticals Inc. (ABEO) Will Announce Quarterly Sales of $270,000.00
www.americanbankingnews.com - May 7 at 2:34 AM
 Brokerages Anticipate Access Pharmaceuticals Inc. (ABEO) to Post -$0.19 EPS Brokerages Anticipate Access Pharmaceuticals Inc. (ABEO) to Post -$0.19 EPS
www.americanbankingnews.com - May 5 at 5:08 PM
Access Pharmaceuticals (ABEO) Given a $30.00 Price Target at HC WainwrightAccess Pharmaceuticals (ABEO) Given a $30.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 3 at 12:52 PM
Kensho's genetic engineering indexKensho's genetic engineering index
finance.yahoo.com - April 27 at 3:54 PM
Access Pharmaceuticals Inc. (ABEO) Given Consensus Rating of "Buy" by BrokeragesAccess Pharmaceuticals Inc. (ABEO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 26 at 1:42 PM
BidaskClub Downgrades Access Pharmaceuticals (ABEO) to HoldBidaskClub Downgrades Access Pharmaceuticals (ABEO) to Hold
www.americanbankingnews.com - April 26 at 1:32 PM
Contrasting Mallinckrodt (MNK) and Access Pharmaceuticals (ABEO)Contrasting Mallinckrodt (MNK) and Access Pharmaceuticals (ABEO)
www.americanbankingnews.com - April 26 at 3:16 AM
New Review of Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies ...New Review of Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies ...
www.prnewswire.com - April 24 at 4:02 PM
Catalyst Pharmaceuticals Introduces New Corporate WebsiteCatalyst Pharmaceuticals Introduces New Corporate Website
globenewswire.com - April 24 at 4:02 PM
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIAAbeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
finance.yahoo.com - April 23 at 10:04 AM
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten DiseaseAbeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
finance.yahoo.com - April 20 at 4:09 PM
Access Pharmaceuticals (ABEO) Receives Buy Rating from HC WainwrightAccess Pharmaceuticals (ABEO) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 20 at 11:53 AM
Access Pharmaceuticals Inc. (ABEO) Expected to Post Quarterly Sales of $270,000.00Access Pharmaceuticals Inc. (ABEO) Expected to Post Quarterly Sales of $270,000.00
www.americanbankingnews.com - April 20 at 2:32 AM
Access Pharmaceuticals (ABEO) Lifted to "Buy" at Zacks Investment ResearchAccess Pharmaceuticals (ABEO) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 11:31 AM
Access Pharmaceuticals Inc. (ABEO) Expected to Post Earnings of -$0.19 Per ShareAccess Pharmaceuticals Inc. (ABEO) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 18 at 5:18 PM
Access Pharmaceuticals (ABEO) Stock Rating Lowered by BidaskClubAccess Pharmaceuticals (ABEO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 15 at 2:21 PM

SEC Filings

Abeona Therapeutics (NASDAQ:ABEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abeona Therapeutics (NASDAQ:ABEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abeona Therapeutics (NASDAQ ABEO) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.